Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation

Parkinsonism Relat Disord. 2008;14(2):114-9. doi: 10.1016/j.parkreldis.2007.06.012. Epub 2007 Sep 5.

Abstract

Objective: To describe the long-term outcome in 50 consecutive advanced Parkinson's disease (PD) patients treated with subthalamic nucleus deep brain stimulation (STN-DBS).

Method: Assessments were carried out at baseline, 6 months, 2 years, and 5 years postoperatively.

Results: Compared to baseline scores without medication, we found a highly significant improvement of UPDRS III with stimulation, maintained at 5 years (p<0.001). This improvement, however, tended to diminish over time. Dyskinesia and off periods were also improved (p<0.0001 for both). Seventeen patients died during follow-up, who tended to be older at surgery (p<0.01).

Conclusions: STN-DBS is an effective treatment for advanced PD patients, and the beneficial effect is maintained at 5 years. However, worsening occurs over time due to disease progression.

MeSH terms

  • Aged
  • Antiparkinson Agents / therapeutic use
  • Cohort Studies
  • Deep Brain Stimulation* / adverse effects
  • Electrodes, Implanted
  • Female
  • Follow-Up Studies
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Microelectrodes
  • Middle Aged
  • Movement / physiology
  • Parkinson Disease / mortality
  • Parkinson Disease / therapy*
  • Prospective Studies
  • Stereotaxic Techniques
  • Subthalamic Nucleus*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antiparkinson Agents